A CONTINUUM OF CARE
Oncologists discuss the role of CYRAMZA in second-line options.WATCH NOW
EVALUATING THE RAINBOW TRIAL
Your peers discuss how the pivotal phase III trial has influenced their practice.
DR. PHILIP SHARES HIS EXPERIENCE
Leading oncologist discusses his experience with CYRAMZA.
DR. KIM SHARES HIS EXPERIENCE
See a colleague discuss his experience with CYRAMZA for a patient in the second-line setting.
NATIONAL GUIDELINES FOR CYRAMZA
Listen to your peers discuss NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) for recommendations for ramucirumab
AN OPTION FOR THE FIGHT
Your peers discuss the importance of having an approved second-line option for patients with gastric and GEJ adenocarcinoma.
A FIGHTING CHANCE
Listen to your peers open up about their role as advocates for patients with gastric and GEJ adenocarcinoma.